The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatoid Arthritis Practice Performance Project Spots Problems in RA Management

Rheumatoid Arthritis Practice Performance Project Spots Problems in RA Management

June 15, 2015 • By Erin Arnold, MD, William Arnold, MD, Douglas Conaway, MD, Gary Crump, MD, Edmund LaCour, MD, James Mossell, DO, Glen Parris, MD, Kathleen Thomas, DO, David Sikes, MD, Anne Winkler, MD, PhD, MACP, Timothy Harrington, MD, & James Bower, MPA

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Rheumatologists have growing concerns about how we manage rheumatoid arthritis (RA) and the disease outcomes we are achieving.1 Over the past two years, clinician rheumatologists have begun working together to address these problems through the Rheumatoid Arthritis Practice Performance (RAPP) Project, a nationwide clinical quality-improvement initiative. The RAPP Project has now grown to 168 participants managing more than 80,000 RA patients. We will describe the problems RAPP clinicians have identified within our current RA management and highlight several high-impact improvements we are testing and implementing.

You Might Also Like
  • Kidney Problems More Prevalent in Patients with Rheumatoid Arthritis
  • Rheumatology Informatics System for Effectiveness Registry Can Help Physicians Improve Practice Performance
  • Rheumatologists May Help Patients with Rheumatoid Arthritis Overcome Obstacles to Sex
Explore This Issue
June 2015

Disease Registry

When the RAPP Project initially asked its participants how many RA patients they manage, what percentages of their RA population have active disease or controlled disease and what percentage are overdue for intended office visits, they had no answers. When they then began using a simple disease registry to manage their RA populations as part of this quality-improvement project, most identified many more RA patients than they had imagined. They also learned that the frequencies of their assessments for patients with controlled, low, moderate and high disease activity fell far short of those recommended by the Treat-to-Target Task Force, the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR).2-4 Evidence of these disease assessment gaps was presented at the 2014 ACR/ARHP Annual Meeting (see Figure 1).5,6

Figure 1: Multi-biomarker assessment data from the aggregated populations of 44 RAPP Project rheumatology practices: Unassessed and overdue patients.

(Click for larger image)
Figure 1: Multi-biomarker assessment data from the aggregated populations of 44 RAPP Project rheumatology practices: Unassessed and overdue patients.

Treat-to-Target RA Management under Current Practice Models

The population management registries of RAPP Project participants have documented that assessing RA disease activity during physician office visits creates an unmanageable workload. We not only lack the visit capacity to see, assess and manage our RA patient populations at the recommended frequencies, but we are also unable to consistently do all the necessary work ourselves for individual patients during these scheduled visits.

Figure 2: Example of RAPP practice visit capacity analysis.

(Click for larger image)
Figure 2: Example of RAPP practice visit capacity analysis.

Consider the evidence. RAPP Project practices have, on average, 585 RA patients per rheumatologist full-time equivalent (range 67–1,800), representing about 40% of the established patients seen in a typical week.5 Practices with mid-level providers predictably manage more patients per rheumatologist, but experience similar visit capacity issues.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Treat-to-Target Task Force recommends assessing patients with moderate and high disease activity monthly, and those with controlled and low disease activity every three to six months.2 Many RAPP clinicians feel it’s appropriate to perform assessments at intervals of three months for patients with moderate or high disease activity and six months for those with controlled or low disease activity, allowing that some patients will be scheduled more or less frequently as their needs require. Yet even with these more lenient disease assessment frequencies, our median percentage overdue for the moderate and high cohort is 66% and for the controlled and low cohort is 52%.6 Moreover, these percentages overdue remain stable from month to month within individual practices, despite RAPP physicians fully intending to perform assessments at every scheduled visit and having access to lists of overdue patients from our registries.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Practice Management, Quality Assurance/Improvement, Rheumatoid Arthritis Tagged With: patient care, Practice Management, Quality, Rheumatoid Arthritis Practice Performance, rheumatologistIssue: June 2015

You Might Also Like:
  • Kidney Problems More Prevalent in Patients with Rheumatoid Arthritis
  • Rheumatology Informatics System for Effectiveness Registry Can Help Physicians Improve Practice Performance
  • Rheumatologists May Help Patients with Rheumatoid Arthritis Overcome Obstacles to Sex
  • Glucocorticoid Use in Rheumatoid Arthritis Management Focus of Ongoing Debate

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)